The transcription factor Forkhead box protein P1 (FOXP1) is highly expressed in a proportion of diffuse large B-cell lymphoma (DLBCL). In this report, we provide cytogenetic and fluorescence in situ hybridization (FISH) data showing that FOXP1 (3p13) is recurrently targeted by chromosome translocations. The genomic rearrangement of FOXP1 was identified by FISH in three cases with a t(3;14)(p13;q32) involving the immunoglobulin heavy chain (IGH) locus, and in one case with a variant t(2;3) affecting sequences at 2q36. These aberrations were associated with strong expression of FOXP1 protein in tumor cells, as demonstrated by immunohistochemistry (IHC). The cases with t(3p13) were diagnosed as DLBCL ( Â 1), gastric MALT lymphoma ( Â 1) and B-cell non-Hodgkin's lymphoma, not otherwise specified ( Â 2). Further IHC and FISH studies performed on 98 cases of DLBCL and 93 cases of extranodal marginal zone lymphoma showed a high expression of FOXP1 in approximately 13 and 12% of cases, respectively. None of these cases showed, however, FOXP1 rearrangements by FISH. However, over-representation of the FOXP1 locus found in one additional case of DLBCL may represent another potential mechanism underlying an increased expression of this gene.
Introduction
FOXP1 (Forkhead box protein P1) is a member of the large family of functionally diverse FOX transcription factors that contain a DNA-binding domain called either the winged-helix or forkhead domain. 1 These transcription factors, identified in organisms ranging from yeast to humans, have been implicated in a variety of cellular processes and play an important role in development. 2, 3 Spontaneous mutations of these molecules have been identified in various congenital disorders, including speech and language disorders (FOXP2) 4 and X-linked autoimmunity-allergic dysregulation (FOXP3). 5 Increasing evidence indicates that FOX proteins play a crucial role in various aspects of immune regulation, from lymphocyte survival to thymic development. 6 FOX transcription factors are also implicated in carcinogenesis through retroviral integration, transcriptional regulation, chromosomal translocation and gene amplification. 7 The latter events are illustrated by the FOXO3(AF6q21)-MLL and FOXO4(AFX)-MLL fusions in acute leukemia, [8] [9] [10] PAX3-and PAX7-FOXO1 (FKHR) rearrangements in alveolar rhabdomyosarcoma 11, 12 and amplification/overexpression of FOXA1 in esophageal and lung cancer. 13 The FOXP1 gene has been mapped to chromosome 3p14.1 14 (currently 3p13; www.ensembl.org), a chromosomal locus shown to be disrupted in a range of solid tumors. 15 Differential expression of this transcription factor has been found in both normal and malignant tissues; however, its biological role is not well understood. Gene expression profiling and immunophenotypic studies showed that FOXP1 is expressed in normal activated B cells and overexpressed in a subset of diffuse large B-cell lymphoma (DLBCL) with a predominantly nongerminal center (non-GC) phenotype. 14, [16] [17] [18] The significance of FOXP1 overexpression in lymphoma is debated, and the recent reports of Barrans et al 17 and Banham et al 19 suggest that it carries independent prognostic significance and correlates with a poor survival of patients with DLBCL. So far, the mechanism or mechanisms underlying overexpression of FOXP1 in DLBCL are unknown.
In this study, we report the results of our genetic and immunophenotypic investigations performed on a large series of B-cell non-Hodgkin's lymphoma (NHL). These investigations led to the identification of four cases (1 Â DLBCL, 1 Â MALT lymphoma, 2 Â B-NHL, not otherwise specified (NOS)) with chromosomal translocations involving the FOXP1 gene and one case (DLBCL) with genomic over-representation of the gene. These genomic aberrations were associated with a strong nuclear expression of FOXP1 protein demonstrated by immunohistochemistry (IHC).
Materials and methods

Patients
Cases with the 3p aberrations (in total 31) were collected from the files of the Center for Human Genetics, K. U. Leuven. This series include four cases with t(3p13) further referred as index cases. Tumor material of the index cases included three nodal biopsies from time of diagnosis (case 1 and 2) or relapse (case 3), and one bone marrow aspirate (case 4; relapse). In addition, 98 well-documented DLBCL and 93 extranodal and nodal MZL cases collected in the Department of Pathology, K.U. Leuven, were analyzed. The DLBCL cases comprised 58 cases with GC phenotype and 40 cases with non-GC type, determined according to Hans et al. 18 Among the 93 MZL cases, 31 were localized in the stomach, 20 in the ocular adnexa, nine in the lung, eight in the spleen, seven in the skin, six in the lymph node, three in the colon, three in the salivary gland, two in the nasopharynx and single cases in the tonsil, thyroid gland, prostate and the breast.
Cytogenetics and fluorescence in situ hybridization (FISH)
G-and R-banding analysis and FISH were performed according to standard procedures. The probes used are listed in Table 1 17 as negative (score 0), positive (score 1, when a proportion of cells showed nuclear staining) and strongly positive (score 2, when there was a uniform strong nuclear staining pattern in nearly all tumor cells).
Results
Three lymphoma cases with a novel t(3;14)(p13Bp14;q32) were identified by conventional cytogenetics ( Table 2 ). The IGH Other abbreviations: F, female; M, male; MALT, mucosa-associated tissue; MZL, marginal zone lymphoma; DLBCL, diffuse large B-cell lymphoma; B-NHL, B-cell non Hodgkin's lymphoma; FL, follicular lymphoma; NOS, not otherwise specified; TNF, tumor necrosis factor; LN, lymph node; BM, bone marrow.
FOXP1 rearrangements in B-cell lymphoma I Wlodarska et al (14q32) involvement in this translocation was further demonstrated by FISH with a dual-color LSI IGH break apart assay ( Figure 1 ). The split of red and green signals hallmarking IGH rearrangement was observed in metaphases and/or interphase nuclei from all three cases (example in Figure 2a ). To identify the 3p partner gene targeted by this translocation, initial metaphase FISH studies with a set of 3p13-p14 BAC clones were performed on case 1. Results are schematically presented in Figure 1 . FISH analysis mapped the 3p breakpoint to RP11-154H23 (3p13) that showed split signals on both derivative chromosomes (a regular signal on the der(3) and a very small signal on the der(14), Figure 2b ). Since this BAC clone covers part of the 5 0 end of FOXP1 (www.ensembl.org), rearrangement of this gene was further examined using three additional clones for FOXP1. Two of them, RP11-79P21 and RP11-905F6 (the 3 0 end of FOXP1), hybridized to the der(14), and RP11-713J07 (flanking the 5 0 end of FOXP1) gave a signal on the der(3). BAC clones RP11-79P21 and -905F6 labeled with Spectrum Green-dUTP, and RP11-154H23 and -713J07 labeled with Spectrum Orange-dUTP were tested as a dual-color FOXP1 break apart assay on case 1 (Figure 2c ). In spite of that, RP11-154H23 covers the breakpoint, we included this clone to a break apart assay, because a very small signal from this BAC found on the der(14) (Figure 2b ) was not observed on interphase cells. The dual-color FOXP1 assay was further applied on the remaining two cases with t(3;14). One fusedone red-one green FISH signal pattern observed on abnormal metaphases and/or interphase nuclei from cases 2 and 3 indicated the t(3;14)-associated rearrangement of FOXP1 (Figure  2d and e). 
Figure 2
Examples of FISH and IHC analysis performed in case 1 (a, b, c, h), case 2 (d, i), case 3 (e, j), case 4 (f) and case 5 (g). Applied probes include LSI IGH (a), RP11-713J07 (red) and RP11-154H23 (green) (b), double-color FOXP1 assay (c-e and g), RP11-551D18 (green) and RP11-211K17 (red) (f). IHC was performed using the JC12/FOXP1 antibody. Long and short arrows in (a-c) and (e) indicate the der(3) and der (14) , and in (f), the der(3) and der(2), respectively.
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Next, we examined the genomic status of FOXP1 in additional 28 cases of various B-cell malignancies with cytogenetically documented 3p11-p21 chromosome aberrations by FISH. In one case with a t(2;3)(q36;p13), we detected two fused signals (normal chromosome 3 and the der(3)) and one extra green signal on the der(2), hallmarking the associated rearrangement of FOXP1. This case (no 4 in Table 2 ) was further investigated by FISH with SpectrumOrange-labeled RP11-905F6 and SpectrumGreen-labeled RP11-79P21 that hybridized, respectively, to the der(3) and der(2) (Figure 2f) . A cryptic involvement of IGH in this case was excluded by FISH with LSI IGH that hybridized to both chromosomes 14. FISH with a set of chromosome 2 BACs (Figure 1 ) narrowed the reciprocal breakpoint to a 2.9 Mb region at 2q36.1-q36.3 flanked by RP11-551D18 (224.26 Mb) and RP11-211K17 (227.15 Mb).
Moreover, we identified one case of DLBCL with a partial tetrasomy 3 and additional subclones with up to 16 FOXP1 signals (case 5 in Figure 2g ) found in more than 80% of metaphases and interphase cells. The remaining 26 cases with 3p11-p21 chromosome aberrations (including reciprocal translocations, additions and 3p deletions) revealed breakpoints outside FOXP1.
To examine whether genomic alterations of FOXP1 are associated with aberrant expression of the FOXP1 protein, paraffin sections from all three available cases with t(3;14) and the DLBCL case with multiple copies of FOXP1 were immunostained with JC12, the FOXP1-specific monoclonal antibody. 14, 19 In all analyzed cases, uniformly strong nuclear expression of FOXP1 was observed in nearly all tumor cells (score 2) (examples in Figure 2h-j) .
The cases with genomic rearrangements of FOXP1 were diagnosed as MALT lymphoma of the stomach (case 1), non-GC type DLBCL (case 2) and B-NHL, NOS (cases 3 and 4). Case 3 showed a follicular growth pattern and lack of BCL2 expression, and was originally diagnosed as BCL2-negative follicular lymphoma. Immunophenotypic analysis of the only available bone marrow cells from case 4 showed a proliferation of small B cells expressing HLA DR, CD19, CD20, CD24, CD5, CD22 and Ig lambda/IgM. Further subtyping of this lymphoma was, however, impossible.
To determine the frequency of FOXP1 rearrangements in DLBCL and MALT lymphoma, we further stained a series of 98 DLBCL and 93 extranodal MZL cases (coming from one institution and partially documented by cytogenetics) with the JC12 antibody. Using scoring criteria described by Barrans et al, 17 we identified a strong nuclear expression of FOXP1 in 12 DLBCL (three with GC-and nine with non-GC phenotype) and 10 MZL cases (three in the skin, two in ocular adnexa and salivary lymph node each, and single cases in the stomach, nasopharynx and spleen) ( Table 3 ). The remaining cases were either negative or showed a variable staining with JC12. All but one of these FOXP1 positive cases with available archival material were further subjected to interphase FISH with the previously established dual-color FOXP1 assay (the remaining FOXP1-positive MZL case not analyzed by FISH, had t(14;18)(q32;q21) targeting IGH and MALT1). No case displayed a FISH pattern indicative of the gene rearrangement. Five MZL and seven DLBCL cases showed, however, an increased number of FOXP1 signals (mostly 3). The interphase FISH findings corresponded well with cytogenetic data available for the majority of these cases, displaying trisomy 3 in cases with three FOXP1 signals.
Discussion
We identified four lymphoma cases with translocations affecting FOXP1, a gene highly expressed in a subset of DLBCL. Three of these cases showed a t(3;14)(p13;q32). The breakpoints of this translocation were mapped by FISH to the 5 0 end of FOXP1 and within the IGH locus, respectively. Given the structure of other well-documented translocations in B-NHL, like t(8;14)(q24;q32) and t(14;18)(q32;q21), we presume that the t(3;14)(p13;q32) juxtaposes FOXP1 with IGH enhancers and deregulates its expression, as shown by a strong nuclear FOXP1 immunostaining in all three cases.
Interestingly, the rearrangement of FOXP1 in the fourth case was associated with a novel t(2;3)(q36;p13). In contrast to t(3;14), the FOXP1 breakpoint in this translocation was narrowed down to the 3 0 region bordered by exon 5 and exon 7 (flanking clones RP11-905F6 (71.339-71.558 Mb) and RP11-79P21 (71.01-71.190 Mb) covering exons 3-5 and exons 7-20, respectively). The reciprocal breakpoint was assigned by FISH to 2q36.1-q36.3. This 2.9 Mb region contains at least 10 genes (www.ensembl.org). However PAX3, an attractive candidate located at 2q36 known to fuse to FOXO1 (FKHR) in alveolar rhabdomyosarcoma, 11 is outside of the breakpoint region (222.9 Mb). Based on FISH results, we propose that the der(2)t(2;3)(q36;p13) harbors the 5 0 sequences of the 2q36 partner gene fused with the 3 0 sequences of FOXP1 (exons 7-20) encoding the zinc finger, leucine zipper, forkhead and acidic rich domains, and the der(3) contains the 5 0 sequences of FOXP1 encoding the poly Q and glutamine-rich domains fused with the remaining domains of the partner gene. This is being investigated. Including case 1; NA, not analyzed.
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The targeting of FOXP1 by two types of chromosome translocations in lymphoma is intriguing but not unique. MALT1 is also affected by analogous translocations: t(11;18)(q21;q21) that fuses MALT1 with API2 and generates a chimeric protein, 20 and t(14;18)(q32;q21) that upregulates the entire MALT1 juxtaposing it to IGH.
21
One of present cases was diagnosed as DLBCL, another one as MALT lymphoma and the two remaining B-NHL cases could not be subtyped. Particularly interesting is our finding of the t(3;14)/IGH-FOXP1 rearrangement in case of DLBCL, because of the postulated role of FOXP1 in the pathogenesis of this disorder. Global gene expression profiling studies and IHC analysis led to the identification of a high expression of FOXP1 in a subset of DLBCL with a predominantly non-GC phenotype. 14, 16, 18 Other studies suggested association of this event with a poor clinical outcome of DLBCL patients. 17, 19 Our results indicate that at least in some of these cases chromosome translocations may underlie the aberrant FOXP1 expression. Moreover, over-representation of the FOXP1 locus (4-16 copies) found in one additional DLBCL case may represent another potential mechanism for increased expression of this gene.
In our series of 98 DLBCL cases (excluding case 2) studied by IHC, 12 cases showed a strong expression of FOXP1. Three of them displayed a GC phenotype and nine a non-GC phenotype. Our findings are in agreement with that of Barrans et al 17 and Banham et al, 19 although the frequency of FOXP1-positive cases in our series of DLBCL is lower (13% (including case 2) vs 18% in Barrans et al 17 and 40% in Banham et al 19 ) . None of these additional DLBCL cases expressing FOXP1 showed, however, rearrangement of the gene by FISH. Similar results were obtained by analyzing FOXP1 expression in additional 93 extranodal MZL lymphomas (excluding case 1). A total of 10 FOXP1-positive cases (three in the skin, two in the ocular adnexa and salivary lymph node each, and single cases in the stomach, nasopharynx and spleen) were identified (11.7% including case 1(stomach)), but none showed genomic aberration of FOXP1. This indicates that t(3p13/FOXP1) is a rare genetic event in DLBCL and in extranodal MZL (Table 3) , as seen in Mitelman Database of Chromosome Aberrations in Cancer, 22 and raises the question how FOXP1 expression is induced in the other cases. It is worth to note, however, that five of 10 MZL cases and seven of 12 DLBCL cases with a strong expression of FOXP1 showed trisomy 3 documented by cytogenetics and FISH. This may suggest an association between occurrence of the extra copy of the FOXP1 locus and aberrant expression of its protein. However, several other MZL and DLBCL cases with trisomy 3 showed negative staining for FOXP1 (data not shown), indicating that trisomy 3 is not sufficient for overexpression of the protein. Trisomy 3, frequently accompanied by trisomy 18, is a characteristic feature of MZL being found in up to 60% of cases. 23 Thus, the finding of trisomy 3 in 45% of FOXP1-positive extranodal MZL cases possibly just reflects this known association. More interesting, however, is the finding of trisomy 3 in 60% of FOXP1-positive DLBCL (associated with trisomy 18 in 70% of these cases; data not shown). This observation suggests that a subset of non-GC DLBCL, especially these harboring trisomy 3 (with or without trisomy 18), might be related to MZL.
So far, little is understood about how the FOXP1 transcription factor mediates signaling and affects gene regulation. The MALT1 and BCL10 genes, two genes known to be involved in pathogenesis of MALT lymphoma, play a crucial role in the antigen receptor signaling pathway leading to activation of NFkB (reviewed in Thome 24 ) . It has been shown that chromosomal translocations targeting these genes perturb a common step in this signaling pathway and possibly contribute to lymphomagenesis by causing inappropriate activation of NF-kB (reviewed in Isaacson 25 ). Further studies are warranted to elucidate whether also FOXP1 is involved in the NF-kB pathway.
Very recently, involvement of FOXP1 in the pathogenesis of MALT lymphoma has also been identified by Streubel et al, 26 who reported one case of MALT lymphoma of the thyroid with the same t(3;14) involving FOXP1. Moreover, the authors examined a series of 91 MALT lymphoma, eight splenic and six nodal MZL cases by interphase FISH (IHC analysis of FOXP1 expression was not performed), and found FOXP1 rearrangement in nine MALT cases (three of the thyroid, four of the ocular adnexa and two of the skin; any of the stomach). Despite of the strikingly different incidence of FOXP1 rearrangements (10% in study of Streubel et al 26 vs approximately 1% in our study), these compiled data indicate that FOXP1 is a new target in the pathogenesis of MALT lymphoma. The significance of this gene is additionally supported by our novel finding of a strong expression of the FOXP1 protein in approximately 12% of extranodal MZL lymphoma.
In summary, we provided cytogenetic and FISH data indicating that the FOXP1 gene is recurrently targeted by chromosome translocations in B-NHL, including DLBCL and MALT lymphoma. These aberrations are associated with a strong expression of FOXP1 protein, as shown by IHC. The overexpression of FOXP1 demonstrated in additional MZL and DLBCL cases with a normal FISH status of FOXP1 warrants further molecular investigations.
